tbuckley/cabot-search huggingface dataset:
ASSOCIATION OF METABOLIC HEALTH AND OBESITY WITH CORONARY ARTERY DISEASE PHENOTYPE
Authors: Andreas Anselm Kammerlander, Thomas Mayrhofer, Neha J. Pagidipati, Pamela S. Douglas, Maros Ferencik, Geoffrey S. Ginsburg, Nathan Bihlmeyer, Svati Shah, Udo Hoffmann
Journal: Journal of the American College of Cardiology (2020)
Bearing the brunt of covid-19: older people in low and middle income countries
Authors: Peter Lloyd-Sherlock, Shah Ebrahim, Leon Geffen, Martin McKee
Journal: BMJ (2020)

The global response to covid-19 has been described as being "too little, too late." 1 National and international efforts are now gathering pace.Those involved in these efforts can draw on a rapidly growing body of research, much summarised in regularly updated guidelines published by national and international authorities, covering the latest information on the virus, its mode of transmission, its spread, and the susceptibility of different groups within the population.Although many aspects of this new infection remain uncertain, one thing is already clear.The risk of dying from covid-19 increases with age, and most of the deaths observed are in people older than 60, especially those with chronic conditions such as cardiovascular disease.This has important implications for the way in which public health and clinical responses should be developed.Yet, to date, guidance largely ignores this issue, not only in high income countries, 2 but in low and middle income countries (LMICs), which contain 69% of the global population aged ≥60 and where health systems are weaker and covid-19 could potentially have the greatest impact.
A SMARTPHONE-BASED APPLICATION POST-PERCUTANEOUS CORONARY INTERVENTION TO MANAGE CARDIOVASCULAR DISEASE RISK
Authors: Kaavya Paruchuri, Phoebe Finneran, Nicholas Marston, Emma Healy, John D. Andreo, Ryan Lynch, Alexander Blood, Bradley Lander, Noreen Kelly, Maria Vivaldi, Kathleen Traynor, Stephen D. Wiviott, Pradeep Natarajan
Journal: Journal of the American College of Cardiology (2020)
Willingness of patients with pancreatic cancer to participate in clinical trials.
Authors: Pelin Cinar, Anitra W. Talley, Jimmy Hwang, Daniel Paul Dohan, Margaret A. Tempero
Journal: Journal of Clinical Oncology (2013)

4055 Background: Recruitment of oncology patients into clinical trials continues to be a challenge as &lt;5% of patients are accrued. Low accrual rates may be due to reduced awareness of trial availability and eligibility by physicians/patients. Our objective was to study the attitudes of patients with pancreatic cancer (PC) regarding clinical trial participation and to identify possible barriers to recruitment. Methods: In this cross-sectional study, we collaborated with Pancreatic Cancer Action Network (PanCAN) and invited patients with PC or their caregivers to complete a survey. The survey that was developed consisted of 22 questions and inquired about patients’ previous clinical trial enrollment experiences and their views on participation. The surveys were collected over a 6-month period via the PanCAN website and regional meetings. Comparison analyses between groups were done by Chi-square and Fisher’s test using STATA software. Results: Of the390 surveys received, 149 were included in the final analyses. 30% of the patients were offered to participate in a trial by their physicians. When asked to participate, 62% of the patients agreed. Of the patients who were not enrolled in a clinical trial, 61% were offered to participate in a trial but did not agree. This suggests that these patients were eligible to participate but declined. Conclusions: Majority of the patients with pancreatic cancer were not offered to participate in clinical trials by their physicians but would have agreed if asked. While low clinical trial recruitment rates for PC may be multifactorial, further research may focus on the important role of physicians in clinical trial recruitment efforts. [Table: see text]
COST-EFFECTIVENESS OF CORONARY ARTERY CALCIUM TO GUIDE PCSK9 INHIBITOR THERAPY AMONG PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
Authors: Jonathan Hong, Marcio Bittencourt, Ron Blankstein, Michael Shapiro, Michael Blaha, Miguel Cainzos-Achirica, Salim Virani, Raul D. Santos, Khurram Nasir
Journal: Journal of the American College of Cardiology (2020)
LEFT ATRIAL STRUCTURE AND FUNCTION OF THE AMYLOIDOGENIC V122I TRANSTHYRETIN VARIANT IN ELDERLY AFRICAN AMERICANS
Authors: Masatoshi Minamisawa, Riccardo M. Inciardi, Brian Claggett, Sarah Cuddy, Candida Cristina Quarta, Amil Shah, Sharmila Dorbala, Rodney Falk, Kunihiro Matsushita, Dalane W. Kitzman, Lin Yee Chen, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2020)
Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer
Authors: N. Yoshimura, S. Kudoh, T. Kimura, S. Mitsuoka, K. Hirata
Journal: Journal of Clinical Oncology (2006)

17013 Background: Single-agent chemotherapy has been considered as standard treatment for elderly patients with non-small cell lung cancer (NSCLC). However recent subset analyses suggest that platinum-based combination chemotherapy may be safely administered to the elderly with good performance status (PS). We evaluated the efficacy and safety of carboplatin and docetaxel in a phase II study of elderly patients aged 70 years or older. Methods: Chemotherapy-naive patients aged ≥70 years with advanced NSCLC (IIIB-IV), ECOG performance status (PS) of 0 or 1, a measurable lesion, and adequate organ functions were enrolled. Patients received carboplatin (AUC 5) and docetaxel (60 mg/m 2 ) administered on day 1 every 3 weeks. The primary endpoint was response rate (RR). This study, with a planned sample size of 25, had 80% power to support the hypothesis that the true RR was &gt;30%, and 5% significance to deny the hypothesis that the true RR was &lt;10%. Results: Between October 2003 and September 2005, 26 elderly patients with NSCLC were enrolled in the study and all patients were treated. Demographics: M/F 17/9; PS 0/1 2/24; median age 75 (range 70–84). Median number of treatment cycles was 4. Responses in the 26 evaluable patients included 1CR; 12PR; 7SD; for an objective RR of 50% (95% CI 31–69%) and a disease control rate of 77%. Median survival period and 1-year survival rate have not yet been reached. Grade 3/4 hematologic toxicities included leukopenia (82%), neutropenia (86%), thrombocytopenia (5%) and anemia (5%). Non-hematologic toxicities were mild with no grade 4 toxicities; grade 3 nausea (9%), anorexia (23%), diarrhea (14%), fatigue (9%), allergic reaction (9%) and infection (18%) were observed. Conclusions: The combination of carboplatin and docetaxel was safe and promising for the treatment of chemotherapy-naive elderly patients with advanced NSCLC. This regimen warrants further evaluation in a phase III trial. No significant financial relationships to disclose.
CARDIAC REHABILITATION MIGHT HELP REFINING THE INDICATION OF HEART TRANSPLANTATION IN PATIENTS WITH ADVANCED HEART FAILURE
Authors: Luiz Eduardo Fonteles Ritt, Pedro Gabriel Melo De Barros E Silva, Eneas Rocco, Renata de Albuquerque, Queila B. de Oliveira, Gustavo Feitosa, João Ramos, Thais Pellegrino, Raquel Mori, Eduardo Darze, Renato Lopes
Journal: Journal of the American College of Cardiology (2020)
Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma
Authors: Shigeru Kusumoto, Yasuhito Tanaka, Ritsuro Suzuki, Takashi Watanabe, Masanobu Nakata, Rika Sakai, Noriyasu Fukushima, Takuya Fukushima, Yukiyoshi Moriuchi, Kuniaki Itoh, Kisato Nosaka, Ilseung Choi, Masashi Sawa, Rumiko Okamoto, Hideki Tsujimura, Toshiki Uchida, Sachiko Suzuki, Masataka Okamoto, Tsutomu Takahashi, Isamu Sugiura, Yasushi Onishi, Mika Kohri, Shinichiro Yoshida, Minoru Kojima, Hiroyuki Takahashi, Akihiro Tomita, Yoshiko Atsuta, Dai Maruyama, Eiji Tanaka, Takayo Suzuki, Tomohiro Kinoshita, Michinori Ogura, Ryuzo Ueda, Masashi Mizokami
Journal: Journal of Hepatology (2020)
MYOCARDIAL T2-MAPPING PREDICTS ADVERSE CARDIAC EVENTS IN HEART TRANSPLANTATION PATIENTS
Authors: Muhannad Abbasi, Roberto Sarnari, Kongkiat Chaikriangkrai, Arif Jivan, Julie Blaisdell, Kambiz Ghafourian, Sadiya Khan, Jane Wilcox, Esther E. Vorovich, Daniel C. Lee, Allen S. Anderson, Jonathan Rich, Clyde W. Yancy, James C. Carr, Michael Markl
Journal: Journal of the American College of Cardiology (2020)
In dementia with aggression and agitation, several interventions help vs usual care
Authors: Calvin Hirsch
Journal: Annals of Internal Medicine (2020)

Source Citation Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for aggressive and agitated behaviors in dementia: a systematic review and network meta-analysis. Ann Intern Med. 2019;171:633-43. 31610547
INTERRELATIONSHIPS OF SYMPATHETIC NERVOUS SYSTEM ACTIVITY WITH ATTENDED AND UNATTENDED BLOOD PRESSURE LEVELS IN ESSENTIAL HYPERTENSIVE PATIENTS
Authors: Konstantinos P. Tsioufis, Elena Manta, Kyriakos Dimitriadis, Dimitris Konstantinidis, Fotis Tatakis, Pantelis Papakonstantinou, Nikos Karaminas, Margarita Dimitriadi, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2020)
EPIDEMIOLOGY, RISK AND PREDICTORS OF AORTIC DISSECTION AND ASSOCIATED IN-HOSPITAL MORTALITY IN ADULTS WITH BICUSPID AORTIC VALVE
Authors: Rushikkumar R. Bhuva, Rupak Desai, Dipen Zalavadia, Ahmed Mahmood, Fariah Asha Haque, Zarna Bambhroliya, Nanush Damarlapally, Kishorbhai Gangani, Gautam Kumar, Rajesh Sachdeva
Journal: Journal of the American College of Cardiology (2020)
Probiotic-directed modulation of gut microbiota is basal microbiome dependent
Authors: Qiangchuan Hou, Feiyan Zhao, Wenjun Liu, Ruirui Lv, Wei Wei Thwe Khine, Jia Han, Zhihong Sun, Yuan-Kun Lee, Heping Zhang
Journal: Gut Microbes (2020)

As an effective means to improve quality of life and prevent diseases, the demand for probiotics and related products has increased in recent years. However, it is still unclear whether a particular probiotic strain will have similar beneficial effects on healthy adults from different regions. In this study, the probiotic Lactobacillus casei Zhang (LCZ) was consumed by healthy adults from six different Asian regions and the changes in gut microbiota were compared using PacBio single molecule, real-time (SMRT) sequencing technology based on samples collected before, during and after consumption of LCZ. Our results reveal that the effect of LCZ consumption on individuals was closely related to the composition of that individual's basal gut microbiota. A Gut Microbiota Variability Index (GMVI) was proposed to quantitatively compare the effects of LCZ on human gut microecology. Subjects from Xinjiang and Singapore regions had the highest and lowest GMVI, respectively. In general, consumption of LCZ increased the relative abundance of certain beneficial bacteria such as Lactobacillus, Roseburia, Coprococcus and Eubacterium rectale, while it inhibited growth of certain harmful bacteria such as Blautia and Ralstonia pickettii. In addition, consumption of LCZ was responsible for the conversion of some participants from Prevotella copri/Faecalibacterium prausnitzii (PF) enterotype to Faecalibacterium prausnitzii/Bacteroides dorei (FB) enterotype and consistently increased the abundance of lactic acid bacteria in the gut. It also increased/enhanced phosphate metabolic modules, amino acid transport systems, and isoleucine biosynthesis, but conversely decreased lipopolysaccharide biosynthesis. These changes could have health benefits for healthy adults.
TEMPORAL TRENDS AND OUTCOMES OF ELECTIVE THORACIC AORTIC ANEURYSM REPAIR VERSUS ANEURYSM RELATED ACUTE AORTIC SYNDROMES, INSIGHTS FROM A NATIONAL DATABASE
Authors: Ayman Elbadawi, Islam Elgendy, Mohamed Omer, Gbolahan Ogunbayo, David Paniagua, Hani Jneid
Journal: Journal of the American College of Cardiology (2020)
Endoscopic full-thickness resection in a recurrent perianastomotic esophagojejunal cancer followed by fully covered metal stent placement for lumen occlusion
Authors: Angelo Caruso, Salvatore Russo, Giuseppe Grande, Flavia Pigò, Santi Mangiafico, Helga Bertani, Rita Conigliaro
Journal: Endoscopy (2020)

An 82-year-old man underwent total gastrectomy for a gastric cancer located in close proximity to the cardia (G2,pT1b,pN2 R0 M0). A follow-up gastroscopy 1 year later showed a flat, slightly elevated lesion in the esophagojejunal anastomosis. The lesion was 15 mm in diameter and had an irregular pit pattern ([Fig. 1]). Biopsy were performed and histologic examination revealed recurrence of the cancer.
LIPOPROTEIN(A), CORONARY ARTERY CALCIFICATION AND CARDIOVASCULAR EVENTS: A COHORT STUDY FROM CHINA
Authors: Na-Qiong Wu, Shuo-Lin Liu, Rynat Rozi, Hui-Wei Shi, Qian Dong, Qiu-Ting Dong, Ying Gao, Yuan-Lin Guo, Jian-Jun Li
Journal: Journal of the American College of Cardiology (2020)
Revisiting 99mTc-MIBI Radioguided Surgery in Management of TENIS Syndrome
Authors: Sarika Prashar, Divya Dahiya, Ashwani Sood, Debajyoti Chatterjee, Ravneet Kaur, Bhagwant Rai Mittal
Journal: Clinical Nuclear Medicine (2020)

Management of patients with thyroglobulin elevated and negative iodine scan is still a challenge with limited options left as the disease stops concentrating iodine. The minimally invasive surgery is the best option for residual/recurrent locoregional disease in postsurgical setup requiring accurate presurgical localization. Intraoperative gamma probe using low-dose tracer has shown its utility in radioguided surgery. The authors present a 46-year-old man with thyroglobulin elevated and negative iodine scan showing FDG-avid left supraclavicular lymph node on whole-body F-FDG PET/CT with physiological uptake on whole-body radioactive iodine scan, where Tc-MIBI radioguided probe helped in carrying out minimally invasive surgery with excision of malignant node.
Polymorphisms in genes OPRM1, β-arrestin 2, STAT6, and COMT and clinical outcome to opioid therapy.
Authors: Sara Cros, Cristina Buges, Alba Ginés, Anna Martinez Cardús, Vicenç Ruiz de Porras, Laia Capdevila, Enric Carcereny, Eva Martinez-Balibrea, Albert Abad
Journal: Journal of Clinical Oncology (2012)

9129 Background: Morphine sulfate is the most widely used opioid in oncologic pain. There is a high variability in response between individuals. The objectives are to correlate the variability in response (R) and tolerability with polymorphisms within OPRM1, β-arrestin 2, STAT6 and COMT gene sequences. Methods: DNA from 44 oncologic patients (pts) with an EVA score &gt; 6 was prospectively analyzed using allelic discrimination techniques and automatic sequencing. Pts (never treated with opioids) received morphine sulfate 10 mg per day. Pain was assessed by EVA score and toxicity was evaluated according to the most common opioid side effects. Symptomatology was reassessed after 72 hours. Chi-squared and Fisher’s tests where used to analyze data. Results: 17 pts (38.6%) responded with an EVA &lt; 3. 6 pts (13.6%) did not experience toxicity, 36 pts (81.8%) had mild side effects and 2 pts (4.5%) had severe side effects. There was no relation between R rate (RR) and tolerance. 76.5% of pts responding to treatment had a CC/CT β-arrestin 2 genotype and this was associated with a better RR (CC/CT R = 46.4% vs. TT R = 25% p = 0.16). The 2 pts having severe side effects belonged to CC/CT group. COMT genotypes AA/GA were associated with a higher RR (83.3%pts) and better tolerance (100% pts with no toxicities). OPRM1 genotype GG was associated with both treatment failure (0% responded) and worse tolerance (any toxicity = 100%; severe side effects = 33%). Only 2,4% pts in the AA/GA genotype experienced some toxicity (p = 0.041). Although STAT6 genotypes were not associated with RR, tolerance was better in those pts with an AA or GA genotype with 97.5% pts showing either mild or no side effects (p = 0.007). Conclusions: Common variants in β-arrestin 2, COMT, OPRM1 and STAT6 genes have shown to predict for opioid-associated response and side effects in oncologic patients. Further studies are needed to assess factors determining the variability in response and tolerance to opioid treatment.
Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer.
Authors: Gayle S. Jameson, Daniel D. Von Hoff, Glen J. Weiss, Donald A. Richards, David A. Smith, Carlos Becerra, Mitchell C. Benson, Zheng Yuan, Deborah A Robins, Michael Turik, Margaret Wagner, Leijun Hu, Boris K. Lin
Journal: Journal of Clinical Oncology (2012)

2516 Background: Skeletal muscle wasting (cachexia) is a prevalent and not readily managed condition in advanced cancer patients. LY2495655 is a humanized monoclonal antibody to myostatin, which has demonstrated positive effects on cachexia measures in animal models. We present phase I trial data on use of LY2495655 in healthy volunteers (Study 1) and interim data from an ongoing phase I study in patients with advanced cancer (Study 2). Methods: Study 1 was a randomized, placebo-controlled, blinded, single-dose, parallel, dose-escalation study evaluating the safety and tolerability of IV or SC LY2495655 (0.7 mg-700 mg). Study 2 is an ongoing nonrandomized, open-label study evaluating the safety and pharmacokinetics (PKs) of LY2495655 in patients with advanced cancer not receiving chemotherapy. Dose cohorts (2 mg-700 mg, ≥3 patients per cohort) were to be treated until the maximum tolerated dose (MTD) was met, or the highest dose (700 mg) cohort was completed. Final locked data from Study 1 and interim data from the dose escalation phase of Study 2 were used in the analyses. Results: In Study 1, 64 healthy volunteers were enrolled (48 LY2495655, 16 placebo). In Study 2, 22 patients had received treatment with LY2495655 at the time of the analysis. In both studies, all doses of LY2495655 were well tolerated (no DLTs were observed and MTD was not reached), and nonlinear PKs were observed (most evident in lower dose levels). In Study 1, thigh muscle volume generally increased with LY2495655. In Study 2, increased muscle volume was observed only at 21-mg and 70-mg doses. Consistent increases in hand grip strength and improvements in functional tests were observed at doses ≥21 mg. Conclusions: There were no unusual safety concerns in healthy subjects or cancer patients. PK results were consistent between the 2 studies. Increases in muscle volume were observed in both studies, with concomitant improvement in functional measures. However, there is no clear trend in dose-dependent efficacy, possibly due to extremely small sample sizes and patient heterogeneity. Enrollment in Study 2 continues with dose expansion cohorts. A Phase 2 study is ongoing in pancreatic cancer patients.
VENTRICULAR ANEURYSMECTOMY: AN OLD MODALITY OF TREATMENT APPLIED TO ELECTRICAL STORM IN A PATIENT WITH MID-VENTRICULAR HYPERTROPHIC MYOCARDIOPATHY
Authors: Nágela Simão Vinhosa Nunes, Joelma Dominato, Mario R. Amar, João C. Tress, Thereza C.D. Estrada, Carmen Tagliaferri, José J. Sobrinho, Daniel G. Neves, Wolney Martins
Journal: Journal of the American College of Cardiology (2020)
INCIDENCE OF NOSOCOMIAL INFECTIONS AND ITS CLINICAL IMPLICATION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION AND CARDIOGENIC SHOCK WITH PERCUTANEOUS MECHANICAL CIRCULATORY SUPPORT DEVICES
Authors: Omar Chehab, Rayan Jo Rachwan, Mohit Pahuja, Shareef Mansoor, Hussam Tabaja, Amjad Kanj, Mustafa Ajam, Paulino Alvarez, Alexandros Briasoulis
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC VALUE OF HEART-TYPE FATTY ACID BINDING PROTEIN COMPARED TO TROPONIN I IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: A LARGE COHORT WITH LONG-TERM FOLLOW-UP STUDY
Authors: Hui-Wen Zhang, Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Ying Gao, Rui-Xia Xu, Qian Dong, Jing Sun, Jian-Jun Li
Journal: Journal of the American College of Cardiology (2020)
EFFICACY OF 24-HOUR ISTAROXIME INFUSION IS SIMILAR BETWEEN CAUCASIAN AND ASIAN PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE
Authors: Robert Segal, Yuhui Zhang, Valentina Carubelli, Phillip Simmons, Steven Simonson, Giuseppe Bianchi, Marco Metra, Jian Zhang
Journal: Journal of the American College of Cardiology (2020)
Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells
Authors: Scott Best, Vi Lam, Tingting Liu, Nur Bruss, Adam Kittai, Olga V. Danilova, Susan Murray, Allison Berger, Nathan D. Pennock, Evan F. Lind, Alexey V. Danilov
Journal: Leukemia (2020)
Therapeutic options for erosive pustular dermatosis of the scalp: a systematic review*
Authors: M.H. Junejo, J. Kentley, M. Rajpopat, X.L. Tan, M. Firouz Mohd Mustapa, C.A. Harwood
Journal: British Journal of Dermatology (2020)

Erosive pustular dermatosis of the scalp (EPDS) is a chronic condition characterized by erosive plaques and subsequent scarring alopecia as a result of local trauma or inflammation. A number of therapeutic approaches have been described in the literature but there is no consensus of opinion on optimal treatment of the disease. To provide evidence‐based recommendations for topical and systemic treatment of adult patients with EPDS by performing a systematic review. The MEDLINE, MEDLINE In‐Process, Embase and Cochrane databases were searched from inception to 26 June 2019 in accordance with the PRISMA guidelines for studies involving adult patients treated for EPDS with at least one reported response to treatment. The study was registered on PROSPERO. Texts were reviewed independently by two authors. The risk of bias and quality of the studies were assessed using the Quality Appraisal Checklist for Case Series Studies. In total 75 studies were included, involving 168 patients. Many treatments have been reported in the literature, with varying degrees of therapeutic success. The results were highly heterogeneous and methodological quality was very low. We were unable to perform a meta‐analysis on the data. The limited available evidence supports use of topical corticosteroids, with or without oral zinc, followed by maintenance therapy with topical calcineurin inhibitors as being effective in managing this condition. Topical photodynamic therapy is also potentially beneficial in the management of EPDS. Prospective, comparative, randomized controlled trials are required in order to provide further evidence to guide treatment.
David Oliver: Doctors should campaign for adult social care reform
Authors: David Oliver
Journal: BMJ (2020)

Social care is in crisis, with no road map to salvation in sight. Last week I wrote about the decades of government inertia in delivering credible, long term solutions to social care funding and provision. At the start of a new five year parliament we hear further vague promises of cross party talks and commitments from the prime minister of a “solution within 12 months.” But, amid competing policy priorities, further drift and fudge are real dangers.1

Yesterday’s budget was hugely disappointing in its lack of funding for social care. It will do nothing to help relieve pressures at a local level or to help push forward new proposals to solve the social care crisis. …
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
Authors: Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury
Journal: Blood (2020)
APPLICABILITY OF NOVEL, CLASS ACTIVATION MAPS (CAM) IN THE DEVELOPMENT OF ARTIFICIAL INTELLIGENCE-GUIDED, SINGLE AND 12-LEAD ECG TO DETECT ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Sameer Mehta, Francisco Fernandez, Carlos Villagrán, Sebastián Niklitschek, Jorge Ávila, Roberto Botelho, Alejandra Frauenfelder, Daniel Vieira, Mariana Ceschim, Sohail Merchant, Akhil Vaid, Gladys Pinto, Isabella Vallenilla, Genesis Perez Del Nogal, Lilly Prieto, Maritza Luna, Daniela Bou Daher, Lorena Pisana, Juhee Lee
Journal: Journal of the American College of Cardiology (2020)